SCHEMBL4634714

SCHEMBL4634714

N#CC1(Cc2ccc(F)cc2)CCN(C(=O)COc2ccc(Cl)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.52
HPGD P15428 2/20 0.52
MAPT P10636 1/20 0.52
RAB9A P51151 1/20 0.52
FKBP1A P62942 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GPR183 P32249 1/20 0.49
CCR1 P32246 1/20 0.48
LMNA P02545 4/20 0.48
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
ENPP2 Q13822 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ATF4 P18848 1/20 0.45
CYP3A4 P08684 2/20 0.45
ABCB11 O95342 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634824 0.88 MDH1 (0.48) POLBMAPTFKBP1AALDH1A1TSHR
SCHEMBL4635591 0.86 ENPP2 (0.61) POLBRAB9AFKBP1AALDH1A1MEN1
SCHEMBL5315889 0.85 POLB (0.56) POLBHPGDMAPTRAB9AFKBP1A
SCHEMBL4635597 0.84 PTGDR2 (0.45) HPGDMAPTTSHRMEN1KMT2A
SCHEMBL4633976 0.84 LMNA (0.53) POLBHPGDMAPTRAB9AALDH1A1
SCHEMBL4634701 0.84 MAPT (0.47) HPGDMAPTTSHRCCR1LMNA
SCHEMBL4634315 0.84 HTT (0.44) HPGDMAPTTSHRCCR1LMNA
SCHEMBL4635527 0.84 FKBP1A (0.44) POLBMAPTRAB9AFKBP1AALDH1A1
SCHEMBL4634285 0.84 CCR1 (0.52) HPGDMAPTALDH1A1TSHRCCR1
SCHEMBL4634615 0.83 SMN1; SMN2 (0.46) MAPTRAB9AFKBP1AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928829-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2008-06-11 EP disclosed
WO-2007073432-A2 PIPERIDINE DERIVATIVES AND METHODS OF USE CHEMOCENTRYX, INC. (US) 2007-06-28 WO disclosed
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-27 US disclosed
WO-2006066948-A1 PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167044-A1 Piperidine derivatives and their use as anti-inflammatory agents CCR1, CCR2, CCR3 POLB 1687/4885HPGD 412/4885MAPT 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.